['ovarian neoplasms', 'ovarian cancer']
['niraparib']

        Inclusion Criteria:

          -  Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.

          -  Patients of childbearing potential must have negative pregnancy serum test within 72
             hours of being dosed

          -  Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous
             epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent
             disease and must have been previously treated with chemotherapy and experienced a
             response lasting at least 6 months to first-line platinum based therapy.

          -  Patients Must have completed 3 or 4 previous chemotherapy regimens.

          -  Patients must have completed their last chemotherapy regimen > 4 weeks prior to
             treatment initiation.

          -  Patients must have measurable disease according to RECIST (v.1.1).

          -  Patients must have formalin-fixed, paraffin-embedded tumor samples available from the
             primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment
             initiation.

          -  Patients must agree to blood samples during screening and at the end of treatment for
             cytogenetic analysis.

        Exclusion Criteria:

          -  Patients must not have any known, persistent (> 4 weeks), ≥Grade 3 hematologic
             toxicity during the last cancer therapy. Patients must not have any known, persistent
             (>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.

          -  Patients must not have received pelvic radiotherapy as treatment for primary or
             recurrent disease within 1 year of the first dose of study treatment.

          -  Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.

          -  Patients must not be considered a poor medical risk due to a serious, uncontrolled
             medical disorder, nonmalignant systemic disease or active, uncontrolled infection.

          -  Patients must not have received a transfusion (platelets or red blood cells) within 4
             weeks of the first dose of study treatment.

          -  Patients must not have known history or current diagnosis of myelodysplastic syndrome
             (MDS) or acute myeloid leukemia (AML).
      